This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
It could also ease the burden on the 225 million women in developing countries, says Ari Altstedter.
The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
Merrill Lynch jumps to first from 7th last year in a smaller market; says its focus is larger deals and clients.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
Unlike India, the US is a free-pricing market.
To ensure transparency, the Third Eye Cinema Fund has roped in various agencies as auditors and advisors.
Top gainers from the Sensex pack are ONGC, HDFC, HUL, RIL and Cipla.
The S&P BSE Sensex gained 115 points to end at 24,338 and the Nifty50 climbed 42 points to close at 7,404.
'Younger people are taking steps to prevent lifestyle diseases.'
'It is fascinating to partner with consumers on the journey of self-discovery and to help shape people's preferences -- that is what I find most exciting,' Nandini Piramal tells Abhineet Kumar and Aneesh Phadnis.
Indian firm to soon launch copycat of anti-breast-cancer drug.
A certain segment of the US pharma industry have become vocal about Indian policies on domestic content requirements and IPR.
Mathew Martoma, a former SAC Capital portfolio manager, faces 20 years in prison for securities fraud and five years for conspiracy
Ranbaxy did its maiden public issue in 1973.
The plan of UID/Aadhaar-based surveillance does not end with the collection of fingerprints and iris scan, it goes quite beyond it and poses a lethal threat to the idea of India, says Gopal Krishna.
'As I became a citizen of the United States of America, I knew I was supposed to be shedding my Indian citizenship, but at the end of the day, Mera dil hai Hindustani,' says Roopa Unnikrishnan, Rhodes Scholar, Commonwealth Gold Medalist and Arjuna Award winner.
Financial numbers can sometimes paint a rosy picture because of changes in the accounting policy or a one-time income.
'The government's proposal to store citizens' data including Aadhaar data under its Digital India initiative on cloud is violative of the citizens' human rights because the cloud is admittedly beyond India's jurisdiction.'
My goal is to implement the Sevak project all over India and make the villages true Gandhian villages -- self sustainable in every way, including health, says Dr Thakor Patel, head of the American Association of Physician of Indian Origin's Public Health Committee. Aziz Haniffa reports
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances